[HTML][HTML] The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

TH Karlsen, N Sheron, S Zelber-Sagi, P Carrieri… - The Lancet, 2022‏ - thelancet.com
Executive summary Liver diseases have become a major health threat across Europe, and
the face of European hepatology is changing due to the cure of viral hepatitis C and the …

The stiffness of living tissues and its implications for tissue engineering

CF Guimarães, L Gasperini, AP Marques… - Nature Reviews …, 2020‏ - nature.com
The past 20 years have witnessed ever-growing evidence that the mechanical properties of
biological tissues, from nanoscale to macroscale dimensions, are fundamental for cellular …

Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

YH Yeo, JS Samaan, WH Ng, PS Ting… - Clinical and …, 2023‏ - pmc.ncbi.nlm.nih.gov
Background/Aims Patients with cirrhosis and hepatocellular carcinoma (HCC) require
extensive and personalized care to improve outcomes. ChatGPT (Generative Pre-trained …

[HTML][HTML] The microbiota in cirrhosis and its role in hepatic decompensation

J Trebicka, J Macnaughtan, B Schnabl… - Journal of …, 2021‏ - Elsevier
Cirrhosis–the common end-stage of chronic liver disease–is associated with a cascade of
events, of which intestinal bacterial overgrowth and dysbiosis are central. Bacterial toxins …

β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo …

C Villanueva, A Albillos, J Genescà, JC Garcia-Pagan… - The lancet, 2019‏ - thelancet.com
Background Clinical decompensation of cirrhosis is associated with poor prognosis.
Clinically significant portal hypertension (CSPH), defined by a hepatic venous pressure …

Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis

C Villanueva, F Torres, SK Sarin, HA Shah… - Journal of …, 2022‏ - Elsevier
Background & Aims Whether non-selective β-blockers can prevent decompensation of
cirrhosis warrants clarification. Carvedilol might be particularly effective since its intrinsic …

EASL clinical practice guidelines: management of hepatocellular carcinoma

PR Galle, A Forner, JM Llovet, V Mazzaferro… - Journal of …, 2018‏ - Elsevier
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …

Towards a new definition of decompensated cirrhosis

G D'Amico, M Bernardi, P Angeli - Journal of hepatology, 2022‏ - Elsevier
There is a universal agreement that the occurrence of clinical complications, such as ascites,
hepatic encephalopathy, gastrointestinal bleeding, and jaundice mark the transition from the …

Hepatic stellate cells as key target in liver fibrosis

T Higashi, SL Friedman, Y Hoshida - Advanced drug delivery reviews, 2017‏ - Elsevier
Progressive liver fibrosis, induced by chronic viral and metabolic disorders, leads to more
than one million deaths annually via development of cirrhosis, although no antifibrotic …

FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2

J Rao, H Wang, M Ni, Z Wang, Z Wang, S Wei, M Liu… - Gut, 2022‏ - gut.bmj.com
Objective Follistatin-like protein 1 (FSTL1) is widely recognised as a secreted glycoprotein,
but its role in modulating macrophage-related inflammation during liver fibrosis has not been …